Pulmonary Clinical Trials

For Patients

If you have been diagnosed with pulmonary diseases such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Pulmonary Hypertension you may be eligible to participate in a clinical research trial. Clinical research trials take place at both the East and West locations for The Oregon Clinic Pulmonary, Critical Care & Sleep Medicine.

There are different types of clinical trials you can be involved with. To learn more about the world of research, we highly recommend reading more on the U.S. National Library of Medicine website by clicking here.

If you are interested in participating in a research trial, please call the contact info that corresponds with your diagnosed disease for more information.

Pulmonary, Critical Care & Sleep Medicine East

  • Asthma | Donovan Redtomahawk | 503-963-3093 | Email
  • Lung Nodule | Meg Day | 503-963-3182 | Email
  • Pulmonary Fibrosis | Meg Day | 503-963-3182 | Email
  • Pulmonary Hypertension | Meg Day | 503-963-3182 | Email

Pulmonary, Critical Care & Sleep Medicine - West

  • Asthma | Lauren Axelrod | 503-935-8822 | Email
  • Pulmonary Hypertension | Lauren Axelrod | 503-935-8822 | Email

For Health Professionals

Actelion AC-055-503 Pulmonary Arterial Hypertension
Lauren Axelrod | 503-935-8822 | Email
US-based, observational, drug registry of Opsumit® (macitentan) new users in clinical practice

AstraZeneca D3250R00023 Severe Asthma
Donovan Redtomahawk | 503-963-3093 | Email
Lauren Axelrod | 503-935-8822 | Email
The CHRONICLE Study:  A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individual with Severe Asthma in the United States

Biodesix BDX-CD-002 Lung Nodule
Meg Day | 503-963-3182 | Email
An Observational Registry Study to Evaluate the Performance of the BDX-XL2 test.  Enrolling subjects 40 and older with maximal dimension of lung nodule > 8mm and < 30mm and Mayo risk prediction algorithm 50% or less.

Boehringer-Ingelheim 1199.247 ILD
Meg Day | 503-963-3182 | Email
A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52weeks in Patients with Progressive Fibrosing Interstitial Lung Disease (INBUILD)

Boehringer-Ingelheim 1199.248 ILD
Meg Day | 503-963-3182 | Email
An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (INBUILD-ON)

DCRI/Boehringer-Ingelheim 1199.174 IPF and ILD
Meg Day | 503-963-3182 | Email
Idiopathic Pulmonary Fibrosis Prospective Outcome (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry.  IPF arm is in long term follow-up. Enrollment continues for Interstitial Lung diseases other than IPF.

Exact Sciences ES-2016-01 Lung Nodule
Meg Day | 503-963-3182 | Email
Blood Sample Collection in Subjects with Pulmonary Nodules and CT Suspicion of Lung Cancer. Subjects 35 years or older with 6-30mm nodule(s) with planned biopsy or other diagnostic procedure

Galapagos Isabela GLPG-1690-CL-303
Meg Day | 503-963-3182 | Email
A Phase 3, randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate the safety and efficacy of two doses of GLPG 1690 in addition to standard of care therapy in subjects with Idiopathic Pulmonary Fibrosis.

GlaxoSmithKline 206860 LEGEND
Donovan Redtomahawk | 503-963-3093 | Email
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) with Inhaled Non-ELLIPTA™ Multiple Inhaler Triple in COPD Patients in the US within a Usual Care Setting in a Prospective Pre-Post Study

GlaxoSmithKline PAS 20138
Donovan Redtomahawk | 503-963-3093 | Email
Post-authorization Safety Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in Chronic Obstructive Pulmonary Disease Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium

PHAR Pulmonary Hypertension Association Registry
Lauren Axelrod | 503-935-8822 | Email
Donovan Redtomahawk | 503-963-3093 | Email
A multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH.  Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.

United Therapeutics APD811-301 Pulmonary Arterial Hypertension
Lauren Axelrod | 503-935-8822 | Email
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

United Therapeutics TDE-HF-301 Pulmonary Hypertension
Lauren Axelrod | 503-935-8822 | Email
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF).